2024-03-07 21:58:08 ET
DBV Technologies S.A. (DBVT)
Q4 2023 Earnings Conference Call
March 07, 2024 05:00 PM ET
Company Participants
Katie Matthews - Investor Relations
Daniel Tassé - Chief Executive Officer
Pharis Mohideen - Chief Medical Officer
Virginie Boucinha - Chief Financial Officer
Conference Call Participants
Jon Wolleben - Citizens JMP
Sushila Hernandez - Van Lanschot Kempen
Presentation
Operator
Apologies for the late start of our conference. Welcome to the DBV Full Year 2023 Financial Results and business Update Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note this event is being recorded.
I would now like to turn the conference over to Katie Matthews, Investor Relations. Please go ahead.
Katie Matthews
Thank you. And again our sincere apologies for the delay in starting today. This afternoon, DBV Technologies issued a press release that outlines our financial results for the 12 months ended December 31st, 2023. This press release is available in the Press Releases section of the DBV Technologies website.
Before we begin, please note that today's call may include a number of forward-looking statements including, but not limited to comments regarding our clinical and regulatory development plans, the design of our anticipated clinical trials, the timing and results of interactions with regulatory agencies, our forecast of our cash runway and the ability of any of our product candidates, if approved, to improve the lives of patients with food allergies.
These forward-looking statements are based on assumptions that are subject to risks and uncertainties that could cause the company's actual results to differ significantly from those suggested by these statements. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements....
Read the full article on Seeking Alpha
For further details see:
DBV Technologies S.A. (DBVT) Q4 2023 Earnings Call Transcript